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Background: Databases of medical claims can be valuable resources for cardiovascular research, such as
comparative effectiveness and pharmacovigilance studies of cardiovascular medications. However, claims data do
not include all of the factors used for risk stratification in clinical care. We sought to develop claims-based algorithms
to identify individuals at high estimated risk for coronary heart disease (CHD) events, and to identify uncontrolled
low-density lipoprotein (LDL) cholesterol among statin users at high risk for CHD events.
Methods: We conducted a cross-sectional analysis of 6,615 participants ≥66 years old using data from the REasons for
Geographic And Racial Differences in Stroke (REGARDS) study baseline visit in 2003–2007 linked to Medicare claims
data. Using REGARDS data we defined high risk for CHD events as having a history of CHD, at least 1 risk equivalent, or
Framingham CHD risk score >20%. Among statin users at high risk for CHD events we defined uncontrolled LDL
cholesterol as LDL cholesterol ≥100 mg/dL. Using Medicare claims-based variables for diagnoses, procedures,
and healthcare utilization, we developed algorithms for high CHD event risk and uncontrolled LDL cholesterol.
Results: REGARDS data indicated that 49% of participants were at high risk for CHD events. A claims-based algorithm
identified high risk for CHD events with a positive predictive value of 87% (95% CI: 85%, 88%), sensitivity of 69% (95% CI:
67%, 70%), and specificity of 90% (95% CI: 89%, 91%). Among statin users at high risk for CHD events, 30% had LDL
cholesterol ≥100 mg/dL. A claims-based algorithm identified LDL cholesterol ≥100 mg/dL with a positive predictive
value of 43% (95% CI: 38%, 49%), sensitivity of 19% (95% CI: 15%, 22%), and specificity of 89% (95% CI: 86%, 90%).
Conclusions: Although the sensitivity was low, the high positive predictive value of our algorithm for high risk for CHD
events supports the use of claims to identify Medicare beneficiaries at high risk for CHD events.
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National Cholesterol Education Program Adult Treat-
ment Panel III (ATP III) guidelines and the newly re-
leased 2013 American College of Cardiology/American
Heart Association Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Cardiovascular
Risk in Adults recommend lipid treatment according to
estimated risk for future coronary heart disease (CHD)
events such as nonfatal myocardial infarction or CHD* Correspondence: elevitan@uab.edu
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unless otherwise stated.death [1-3]. Pharmacotherapy initiation is guided by
low-density lipoprotein (LDL) cholesterol levels and risk
for future CHD or other atherosclerotic events. Risk is
assessed by history of CHD, risk equivalents such as
stroke and diabetes, risk factors such as hypertension
and current smoking, and predicted risk calculated from
risk equations including CHD risk factors [1-3]. Despite
these guidelines, many people eligible for lipid lowering
therapy are untreated or undertreated [4,5].
Novel LDL cholesterol lowering medications are being
evaluated in clinical trials [6,7]. If these medications obtain
regulatory approval, healthcare claims data could be used
for comparative effectiveness and pharmacovigilance studiesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pharmacy claims. Finding a comparison group with a similar
CHD risk profile is more challenging. One potential barrier
is that claims data do not include clinical or laboratory
values that are often used to estimate CHD event risk. Some
data show that claims-based algorithms can be useful in
identifying high risk groups, for example people at high risk
for osteoporotic fracture [9]. However, whether claims-
based algorithms can be used to identify individuals at high
risk for CHD events is not known.
In addition to identifying high risk groups, it would be
of interest in some studies to identify people who may
warrant more intensive treatment based on laboratory
tests; one such group is individuals with elevated LDL
cholesterol levels despite statin treatment. So far there is
not much evidence that healthcare claims can be used
effectively to estimate laboratory values [10]. Advances
in this area could increase the value of healthcare claims for
comparative effectiveness and pharmacovigilance research.
In this paper we describe the development of claims-
based algorithms to identify individuals at high risk for
CHD events according to ATP III guidelines, using Medi-
care claims data on diagnoses, procedures, and healthcare
utilization. We expanded upon existing claims-based defi-
nitions of specific cardiovascular conditions and proce-
dures [11-19] by bringing them into a broader framework
with the goal of identifying the more general concept of
“high risk.” We also describe claims-based algorithms to
identify uncontrolled LDL cholesterol according to ATP
III guidelines among statin users at high risk for CHD
events. In evaluating these algorithms we considered posi-
tive predictive value as the most important measure of
model performance because our aim was to identify high-
risk groups and exclude lower-risk individuals.
Methods
Design, setting, and participants
We conducted a cross-sectional analysis of baseline data
from REasons for Geographic And Racial Differences in
Stroke (REGARDS) study participants linked to Medi-
care data. REGARDS is a population-based cohort of
30,239 adults ≥45 years of age enrolled in 2003–2007 in
the continental United States [20]. Linkage of REGARDS
data with Medicare enrollment data was based on social
security number, which is a unique identifier that was
required to match exactly on all digits; sex, which was
required to match; and birth date, which was required to
match on year and month, year and day, or month and
day allowing a difference of one year. We included 6,615
REGARDS participants who provided study data free of
anomalies such as missing all baseline data collection
forms, were ≥66 years of age at their REGARDS in-
home visit, linked to Medicare, provided a fasting blood
sample, had complete REGARDS data for calculatingCHD event risk according to ATP III guidelines (de-
scribed below), and had been living in the United States,
continuously enrolled in Medicare parts A and B, but
not in a Medicare Advantage plan, for at least one year
immediately prior to their REGARDS in-home visit
(Figure 1). This research was conducted in accordance
with the Declaration of Helsinki. Institutional review
boards of the collaborating institutions (University of
Alabama at Birmingham, University of Vermont, Wake
Forest University, and University of Cincinnati) ap-
proved the REGARDS protocol. Participants gave informed
consent. The REGARDS-Medicare linkage was approved by
the institutional review board at the University of Alabama
at Birmingham.
REGARDS variables
REGARDS baseline data collection included a structured
telephone interview and an in-home visit. The telephone
interview included questions about demographics and
medical history. The in-home visit included two blood
pressure measurements, an electrocardiogram, blood sam-
ple collection, and a medication inventory to assess current
medication use including statins (see Text, Additional file 1).
Using REGARDS data we categorized each partici-
pant’s CHD event risk according to the ATP III guide-
lines 2004 update [1,2]. High risk for CHD events was
defined as (1) having a history of CHD, including myo-
cardial infarction (MI) or coronary revascularization; (2)
having a history of least one of the following risk equiva-
lents: peripheral arterial disease, abdominal aortic aneurysm,
carotid artery disease, stroke, or diabetes; or (3) in the ab-
sence of CHD or risk equivalents, having ≥2 CHD risk fac-
tors with Framingham 10-year CHD risk score >20%. CHD
risk factors included age ≥45 years (men) or ≥ 55 years
(women), family history of premature MI, current smoking,
hypertension, and high-density lipoprotein (HDL) choles-
terol <40 mg/dL. HDL cholesterol ≥60 mg/dL reduced the
risk factor count by one. Framingham 10-year CHD risk
score >20% was defined using age, sex, total cholesterol,
HDL cholesterol, current smoking, and systolic blood pres-
sure [1]. Very high risk for CHD events was defined as
having CHD and at least one of the following: acute
MI in the prior year, diabetes, current smoking, or
metabolic syndrome.
Using the above definitions and REGARDS study data,
we defined the presence of two high risk conditions among
REGARDS-Medicare linked participants (N = 6,615):
 Condition 1: High risk for CHD events
 Condition 2: Very high risk for CHD events
We defined a third high risk condition among REGARDS-
Medicare linked participants who did not have a his-
tory of CHD or risk equivalents (N = 3,720):
REGARDS 
participants 
N = 30,239 
Participants eligible 
for this analysis 
N = 6,615 
Age <66 at 
REGARDS in-home 
visit 
N = 16,477 
Not linked to 
Medicare 
N = 2,694 
Not fasting 
N = 1,747 
Missing REGARDS 
data for calculating 
CHD event risk 
N = 805 
Not residing in 
United States for one 
full year prior to 
REGARDS in-home 
visit 
N = 30 
Not continuously 
enrolled in Medicare 
parts A and B for 
one full year prior to 
REGARDS in-home 
visit 
N = 1,815 




N = 56 
Figure 1 Participant flowchart.
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Also using REGARDS study data, we defined the pres-
ence of uncontrolled LDL cholesterol, using two cut-
points, among REGARDS-Medicare linked participantsat high risk for CHD events who were using statins ac-
cording to the REGARDS in-home visit medication in-
ventory (N = 1,583):
 Condition 4: LDL cholesterol ≥100 mg/dL
 Condition 5: LDL cholesterol ≥70 mg/dL
Medicare Variables
To develop claims-based algorithms we used Medicare
data from January 2000 to the date of the REGARDS in-
home visit (2003 to 2007). Mean time from Medicare
enrollment to the REGARDS in-home visit was 4.6 years
(range: 1.1 to 7.8 years). We identified Medicare vari-
ables using two approaches. First, we pre-specified 25
variables describing demographics, diagnoses, and health-
care utilization indicators that we believed would be asso-
ciated with CHD risk:
 Demographic variables including age, sex, race,
Medicaid eligibility, area-level income, and geographic
region.
 Diagnosis variables including claims-based evidence
of tobacco use, history of hyperlipidemia, history of
hypertension, history of diabetes, acute myocardial
infarction, coronary revascularization, history of
coronary heart disease, history of stroke, history of
abdominal aortic aneurysm, history of peripheral
arterial disease, and history of carotid artery
disease.
 Health care utilization variables including
cardiologist care, endocrinologist care, neurologist
care, number of evaluation and management visits,
hospitalization for any cause, cardiac stress test,
echocardiogram, and electrocardiogram.
Several pre-specified variables were based on published
claims-based definitions (see Text, Additional file 1)
[11-19]. The same 25 pre-specified variables were used
in algorithms for all conditions of interest. Second,
through a data mining procedure we identified add-
itional Medicare variables, including diagnosis and proced-
ure codes. The data mining procedure was adapted from a
previously described algorithm for high-dimensional pro-
pensity scores (for detail see Text, Additional file 1) [21].
The procedure had four steps: (1) identify diagnosis and
procedure codes appearing in REGARDS participants’
linked Medicare claims data, (2) calculate the prevalence of
each code, (3) calculate the odds ratio of each code with
high risk as defined using REGARDS data, and (4) rank the
codes as a function of their prevalence and their odds
ratio with high risk, and select the highest-ranked
codes, excluding collinear variables. The data mining
variables differed for each condition. We did not use
Medicare Part D pharmacy claims data because few
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in-home visit.
Statistical analysis
We used logistic regression and Medicare claims-based
variables to develop algorithms identifying each of three
high risk conditions and uncontrolled LDL cholesterol
defined in REGARDS data. The analysis is described below
for Condition 1, high risk for CHD events. An identical ap-
proach was used for the other conditions. We calculated
beta coefficients and standard errors for high risk associ-
ated with each pre-specified Medicare variable from a
multivariable logistic regression model. We included
interaction terms for sex with other variables if they
had a P value <0.1. We calculated the predicted prob-
ability of being at high risk for each participant from
the beta coefficients, and plotted distributions of pre-
dicted probabilities for people at high risk and for
people not at high risk according to REGARDS data.
We calculated sensitivity, specificity, positive predict-
ive value (PPV), and negative predictive value (NPV)
across the range of predicted probability thresholds
from 0 to 1, and we calculated a c-statistic. We calcu-
lated 95% confidence intervals for the model perform-
ance characteristics by bootstrapping. To report model
performance characteristics in tables we chose the pre-
dicted probability threshold that resulted in 90% speci-
ficity before correcting for optimism (see below). We
built a second model adding variables from the data
mining procedure. We corrected model performance
characteristics for optimism using bootstrap resampling,
which has been recommended as a better method for in-
ternal validation than a split-sample approach [22]. We
cross-classified participants by model-predicted and
observed high risk status to compare characteristics of
true positives, false positives, false negatives, and true
negatives.
We conducted four sensitivity analyses. First, for iden-
tifying high risk, we assigned a predicted probability of 1
for each participant who had evidence in their claims of
a history of CHD, peripheral arterial disease, abdominal
aortic aneurysm, carotid artery disease, stroke, or dia-
betes; and assigned a predicted probability of 0 other-
wise. Second, for identifying high risk, we assigned a
predicted probability of 1 as in the first sensitivity ana-
lysis; and assigned a predicted probability based on a lo-
gistic regression model otherwise. Third, for identifying
very high risk, we assigned a predicted probability of 1
for each participant who had evidence in their claims of
a history of CHD and either acute MI in the prior year
or diabetes; and assigned a predicted probability based on
a logistic regression model otherwise. Fourth, for all five
conditions, we used claims data for only one year prior to
the REGARDS in-home visit to define pre-specifiedand data mining Medicare variables, instead of using
all available claims.
We used SAS software version 9.3 (Cary, NC) for all
statistical analyses.
Results
High risk for CHD events
Among 6,615 REGARDS participants, 49% were at high
risk for CHD events based on REGARDS data. High risk
participants were more likely to be men, have less edu-
cation, be using statins, have lower cholesterol, and
higher levels of other cardiovascular risk factors in-
cluding hypertension and metabolic syndrome, com-
pared with participants not at high risk (Table 1).
Predicted probabilities using pre-specified variables
tended to be higher for participants at high risk and
lower for participants not at high risk (Figure 2, Panel
A). In the model that included pre-specified variables,
a predicted probability threshold of 0.55 yielded a PPV
of 87% (95% CI: 85%, 88%) for identifying high risk for
CHD, and a sensitivity of 69% (95% CI: 67%, 70%); results
were similar after adding data mining variables (Table 2
and see Additional file 1: Figure S1, Panel A). High risk
participants not identified by the algorithm (false nega-
tives) were less likely to be men, be using statins, have
metabolic syndrome, diabetes, and CHD, and had higher
LDL cholesterol, higher blood pressure, and lower blood
glucose, compared with high risk participants correctly
identified by the algorithm (true positives) (Table 3). Non-
high risk participants identified as high risk by the algo-
rithm (false positives) were less likely to be using statins,
to have metabolic syndrome, and had higher total and
LDL cholesterol but lower triglycerides, compared with
true positives.
Very high risk for CHD events
Among 6,615 participants, 14% were at very high risk
for CHD events based on REGARDS data. Predicted
probabilities were uniformly distributed for participants
at very high risk and tended to be low for participants
not at very high risk (Figure 2, Panel B). In the model
using pre-specified variables, a predicted probability thresh-
old of 0.28 yielded a PPV of 52% (95% CI: 49%, 54%) for
identifying very high risk for CHD events and a sensitivity
of 63% (95% CI: 59%, 66%); results were similar after adding
data mining variables (Table 2 and see Additional file 1:
Figure S1, Panel B). Participant characteristics by observed
and model-predicted very high risk status are in Additional
file 1: Table S1.
Framingham CHD risk score >20%
Among 3,720 participants who did not have a history of
CHD or risk equivalents according to REGARDS data,
9% had Framingham 10-year CHD risk scores >20%.
Table 1 Participant characteristics in REGARDS study data
by CHD risk category*




N= 6,615 N= 3,216 N= 3,399
Age, y 73.2 (5.6) 73.9 (5.6) 72.7 (5.5)
Male 49.6 60.0 39.7
Black 30.4 32.9 28.1




Current use of statins 37.6 49.2 26.6
Total cholesterol, mg/dL 187.0 (38.9) 177.8 (38.5) 195.6 (37.3)
LDL cholesterol, mg/dL 109.8 (34.0) 103.4 (33.8) 115.9 (33.1)
LDL cholesterol among
statin non-users, mg/dL
120.4 (33.9) 117.3 (35.4) 122.5 (32.8)
HDL cholesterol, mg/dL 52.1 (16.4) 47.6 (15.1) 56.3 (16.5)
Triglycerides, mg/dL 125.3 (61.5) 133.9 (66.0) 117.1 (55.8)
Family history of MI 19.0 20.9 17.4
Current cigarette smoking 8.9 11.0 6.9
Body mass index, kg/m2 28.1 (5.4) 28.9 (5.4) 27.4 (5.2)
Systolic blood
pressure, mm Hg
130.3 (16.6) 133.2 (17.5) 127.5 (15.1)
Diastolic blood
pressure, mm Hg
75.3 (9.4) 75.6 (9.8) 75.1 (8.9)
Blood glucose, mg/dL 101.4 (27.9) 110.7 (36.3) 92.7 (10.5)
C-reactive protein, mg/L 4.5 (8.5) 5.0 (9.4) 4.0 (7.5)
Hypertension 64.7 75.2 54.8
Metabolic syndrome 39.0 54.4 24.5
Coronary heart disease 24.6 50.6 0.0‡
Acute MI in prior year 1.3 2.8 0.0‡
Peripheral arterial disease 2.6 5.3 0.0‡
Abdominal aortic aneurysm 1.6 3.3 0.0‡
Carotid artery disease 3.2 6.7 0.0‡
Stroke 7.6 15.7 0.0‡
Diabetes 20.8 42.8 0.0‡
Abbreviations: HDL high density lipoprotein, LDL low density lipoprotein
MI myocardial infarction.
*REGARDS participants included in this table are those who were linked to
Medicare data and met all eligibility criteria for this analysis (see Figure 1).
†Numbers are column percentages or means (standard deviations). Income was
missing for 914 participants, education for 4, body mass index for 16, and C-reactive
protein for 164.
‡By definition, participants not at high risk for CHD events did not have a history of
CHD or risk equivalents according to REGARDS study data.
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participants with risk scores >20% and tended to be low
for participants with risk scores ≤20% (Figure 2, Panel C).
In the model using pre-specified variables, a predicted
probability threshold of 0.20 yielded a PPV of 31% (95%
CI: 27%, 36%) for identifying Framingham CHD riskscore >20% and a sensitivity of 47% (95% CI: 43%, 54%);
results were similar after adding data mining variables
(Table 2 and see Additional file 1: Figure S1, Panel C).
Participant characteristics by observed and model-
predicted Framingham CHD risk score >20% status
are in Additional file 1: Table S2.
Uncontrolled LDL cholesterol among statin users at high
risk for CHD events
Among 1,583 participants at high risk for CHD events
who were using statins according to the REGARDS medi-
cation inventory, 30% had LDL cholesterol ≥100 mg/dL,
and 80% had LDL cholesterol ≥70 mg/dL. The pre-
dicted probability distributions overlapped for partici-
pants with and without uncontrolled LDL cholesterol
(Figure 2). In the model using pre-specified variables,
a predicted probability threshold of 0.43 yielded a
PPV of 43% (95% CI: 38%, 49%) for identifying LDL
cholesterol ≥100 and a sensitivity of 19% (95% CI:
15%, 22%) (Table 2 and see Additional file 1: Figure S2,
Panel A). For identifying LDL cholesterol ≥70 the PPV was
86% (95% CI: 83%, 89%) in the model using pre-specified
variables, and increased to 91% (95% CI: 85%, 91%) when
adding data mining variables (Table 2 and Additional file 1:
Figure S2, Panel B). Participant characteristics by observed
and model-predicted uncontrolled LDL cholesterol status
are in Additional file 1: Tables S3 and S4.
Model parameters
Beta coefficients and standard errors for models using
pre-specified Medicare variables are in Additional file 1:
Table S5.
Sensitivity analyses
When we assigned a predicted probability of 1 for par-
ticipants who met a pre-specified claims-based definition
of high risk for CHD events, and a predicted probability
of 0 otherwise, the PPV was 80% (95% CI: 79%, 81%)
and sensitivity was 75% (95% CI: 73%, 77%). Model char-
acteristics were similar when we assigned a predicted
probability of 1 for participants who met a pre-specified
claims-based definition of high risk for CHD events, and
assigned model-based predicted probabilities otherwise.
When we assigned a predicted probability of 1 for
participants who met a pre-specified claims-based
definition of very high risk for CHD events, and
assigned model-based predicted probabilities otherwise,
the PPV was 51% (95% CI: 48%, 54%) and sensitivity was
63% (95% CI: 58%, 66%) (see Additional file 1: Table S6,
and Additional file 1: Figure S3).
When we used only one year of Medicare claims data
prior to the REGARDS in-home visit, the sensitivity de-
creased for identifying high risk for CHD events, very
high risk for CHD events, and Framingham 10-year
A B CCondition 1:
High risk for CHD events
N = 6,615; prevalence = 49%
Condition 2:
Very high risk for CHD events 
N = 6,615; prevalence = 14% 
Condition 3:
Framingham risk score >20% 
N = 3,720; prevalence = 9% 
D ECondition 4:
LDL cholesterol ≥100 mg/dL 
N = 1,583; prevalence = 30% 
Condition 5:
LDL cholesterol ≥70 mg/dL 




threshold for 90% 
specificity
Figure 2 Distributions of predicted probabilities of having a high risk condition or an uncontrolled LDL cholesterol condition
(estimated by Medicare data) by observed presence or absence of the condition (REGARDS study data). Panel A shows Condition 1, high
risk for CHD events, among all eligible participants. Panel B shows Condition 2, very high risk for CHD events, among all eligible participants.
Panel C shows Condition 3, Framingham CHD risk score >20%, among eligible participants without a history of CHD or risk equivalents. Panel
D shows Condition 4, LDL cholesterol ≥100 mg/dL, and Panel E shows Condition 5, LDL cholesterol ≥70 mg/dL, among eligible participants
at high risk for CHD events who were using statins according to the REGARDS in-home visit medication inventory. In each panel the solid
curve represents the distribution of predicted probabilities of having the condition among those observed to have the condition in
REGARDS, the dashed curve represents the distribution of predicted probabilities of having the condition among those not observed to
have the condition in REGARDS, and the vertical dotted line represents the predicted probability threshold corresponding to 90% specificity
for identifying the condition. All results are from models using pre-specified Medicare variables only. Results from models using pre-specified
variables plus data mining variables were similar (data not shown).
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Results for uncontrolled LDL cholesterol among statin
users at high risk for CHD events were similar to the
main results when we used only one year of Medicare
claims data (see Additional file 1: Table S8).
Discussion
In this population of REGARDS study participants, an
algorithm using 25 pre-specified Medicare claims vari-
ables had a PPV of 87% for identifying people at high
risk for CHD events. Additional claims variables identi-
fied through data mining did not substantially improve
the algorithm performance. The high PPV of our algo-
rithm supports the use of claims to identify Medicare
beneficiaries at high risk for CHD events. Our algorithm
could be applied in comparative effectiveness or phar-
macovigilance studies of the outcomes of cardiovascular
medication use among Medicare beneficiaries. For ex-
ample, if novel LDL cholesterol lowering drugs currentlyin development [6,7] come to market, Medicare may be
a setting in which to evaluate the effectiveness and safety
of these drugs. Comparison groups in such studies
should have comparable proportions of people at high
risk for CHD events, and our algorithm could be used to
identify appropriate comparison cohorts. However, the
algorithm had a sensitivity of 69% and missed 31% of
participants at high risk for CHD events. Along with this
low sensitivity, the group identified was not representa-
tive of all participants at high risk for CHD events.
People at high risk for CHD events whom our algorithm
missed were less likely to have CHD and diabetes and to
be using statins, and had higher lipid levels and blood
pressure compared with people at high risk for CHD
events whom the algorithm correctly identified. This
pattern is consistent with claims data being more sensi-
tive for identifying people with diagnosed conditions
than for identifying people with abnormal laboratory
values. Therefore, future use of this algorithm to identify
Table 2 Test characteristics of Medicare claims-based models for identifying high risk conditions or uncontrolled LDL cholesterol conditions defined in
REGARDS study data








PPV (95% CI)‡ NPV (95% CI)‡ C statistic
(95% CI)‡
Among all eligible participants
Condition 1: High risk for CHD events 6,615 49%
Pre-specified 0.55 0.69 (0.67, 0.70) 0.90 (0.89, 0.91) 0.87 (0.85, 0.88) 0.75 (0.73, 0.77) 0.86 (0.85, 0.86)
Pre-specified + data mining 0.52 0.71 (0.69, 0.72) 0.89 (0.88, 0.90) 0.86 (0.84, 0.87) 0.76 (0.74, 0.77) 0.87 (0.86, 0.88)
Condition 2: Very high risk for CHD events 6,615 14%
Pre-specified 0.28 0.63 (0.59, 0.66) 0.90 (0.89, 0.90) 0.52 (0.49, 0.54) 0.94 (0.93, 0.95) 0.84 (0.83, 0.86)
Pre-specified + data mining 0.26 0.66 (0.63, 0.70) 0.90 (0.89, 0.90) 0.52 (0.49, 0.55) 0.94 (0.93, 0.94) 0.86 (0.84, 0.87)
Among eligible participants without history of
CHD or risk equivalents
Condition 3: Framingham risk score >20% 3,720 9%
Pre-specified 0.20 0.47 (0.43, 0.54) 0.90 (0.89, 0.91) 0.31 (0.27, 0.36) 0.95 (0.94, 0.96) 0.82 (0.80, 0.84)
Pre-specified + data mining 0.20 0.46 (0.40, 0.52) 0.90 (0.89, 0.91) 0.31 (0.27, 0.35) 0.95 (0.94, 0.95) 0.81 (0.79, 0.84)
Among eligible participants at high risk for CHD events
who were using statins
Condition 4: LDL cholesterol ≥100 mg/dL 1,583 30%
Pre-specified 0.43 0.19 (0.15, 0.22) 0.89 (0.86, 0.90) 0.43 (0.38, 0.49) 0.72 (0.70, 0.74) 0.60 (0.57, 0.62)
Pre-specified + data mining 0.45 0.20 (0.15,0.24) 0.88 (0.86, 0.89) 0.43 (0.39, 0.48) 0.71 (0.69, 0.73) 0.62 (0.60, 0.65)
Condition 5: LDL cholesterol ≥70 mg/dL 1,583 80%
Pre-specified 0.88 0.19 (0.17, 0.23) 0.86 (0.81, 0.90) 0.86 (0.83, 0.89) 0.21 (0.19, 0.23) 0.59 (0.56, 0.62)
Pre-specified + data mining 0.88 0.25 (0.23, 0.27) 0.85 (0.81, 0.88) 0.91 (0.85, 0.91) 0.23 (0.20, 0.24) 0.60 (0.57, 0.63)
Abbreviations: NPV negative predictive value, PPV positive predictive value.
*Pre-specified Medicare variables: age, sex, race, Medicaid eligible, area-level income, geographic region, evidence of tobacco use, history of hyperlipidemia, history of hypertension, history of diabetes, acute MI, coron-
ary revascularization, history of CHD, history of stroke, history of abdominal aortic aneurysm, history of peripheral arterial disease, history of carotid artery disease, cardiologist care, endocrinologist care, neurologist
care, number of evaluation and management visits, hospitalization for any cause, cardiac stress test, echocardiogram, electrocardiogram. For pre-specified variable definitions and a description of the methods used to
obtain variables through a data mining procedure see Additional file 1.
†For each model, test characteristics are reported for the predicted probability threshold corresponding to an uncorrected specificity of 0.90.




















Table 3 Participant characteristics from REGARDS data by observed (REGARDS) and model-predicted (Medicare) high
risk for CHD events, from the model with pre-specified Medicare variables only
Model-predicted high risk (Medicare) Model-predicted not high risk (Medicare)
Characteristic* Observed high risk
(REGARDS) (true
positives) N = 2,217
Observed not high risk
(REGARDS) (false
positives) N = 343
Observed high risk
(REGARDS) (false
negatives) N = 999
Observed not high risk
(REGARDS) (true
negatives) N = 3,056
Age, y 74.0 (5.7) 74.6 (6.0) 73.6 (5.5) 72.4 (5.3)
Male 63.9 57.4 51.3 37.7
Black 34.6 35.0 28.9 27.3
Income < $35,000/y 58.5 58.0 59.3 54.3
Education≤ High
school graduate
45.7 42 44.6 35.5
Current use of statins 57.5 38.2 30.9 25.3
Total cholesterol, mg/dL 172.0 (37.2) 182.9 (38.6) 190.8 (38.3) 197.0 (36.9)
LDL cholesterol, mg/dL 98.7 (32.3) 106.0 (33.9) 114.0 (34.5) 117.0 (32.9)
LDL cholesterol among statin
non-users, mg/dL
113.3 (35.1) 115.3 (34.8) 122.7 (35.1) 123.1 (32.5)
HDL cholesterol, mg/dL 47.0 (14.4) 53.9 (17.0) 48.9 (16.5) 56.6 (16.5)
Triglycerides, mg/dL 131.2 (65.9) 114.6 (58.1) 139.9 (65.7) 117.4 (55.5)
Family history of MI 21.9 19.0 19.0 17.2
Current cigarette smoking 9.2 6.1 15.0 7.0
Body mass index, kg/m2 29.2 (5.5) 28.4 (5.6) 28.1 (5.2) 27.3 (5.2)
Systolic blood pressure, mm Hg 132.7 (17.6) 129.3 (15.0) 134.2 (17.4) 127.3 (15.2)
Diastolic blood pressure, mm Hg 74.9 (9.7) 75.1 (9.0) 77 (9.9) 75.1 (8.9)
Blood glucose, mg/dL 114.2 (38.4) 95.6 (12.6) 102.9 (29.8) 92.4 (10.1)
C-reactive protein, mg/L 4.9 (9.3) 4.4 (10.7) 5.2 (9.6) 3.9 (7.1)
Hypertension 76.0 66.5 73.5 53.5
Metabolic syndrome 57.8 32.9 46.7 23.6
Diabetes 54.0 0.0† 18.0 0.0†
Coronary heart disease 55.3 0.0† 40.1 0.0†
Acute MI in prior year ‡ 0.0† ‡ 0.0†
Peripheral arterial
disease
5.5 0.0† 4.8 0.0†
Abdominal aortic aneurysm 4.0 0.0† 1.9 0.0†
Carotid artery disease 7.7 0.0† 4.4 0.0†
Stroke 16.2 0.0† 14.5 0.0†
Abbreviations: HDL high density lipoprotein, LDL low density lipoprotein, MI myocardial infarction.
*Numbers are column percentages or means (standard deviations). Income was missing for 914 participants, education for 4, body mass index for 16, and C-reactive
protein for 164.
†By definition, participants not at high risk for CHD events did not have a history of CHD or risk equivalents according to REGARDS study data.
‡The Centers for Medicare and Medicaid Services (CMS) requires the figure be redacted because the cell contained fewer than 11 participants, or would allow a
number fewer than 11 participants to be deduced in another cell.
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ied by careful consideration of generalizability.
Our algorithms did not perform as well for identifying
those at very high risk for CHD events and those with-
out CHD or risk equivalents but with a Framingham 10-
year CHD risk score >20%. Very high risk for CHD
events and Framingham 10-year CHD risk score >20%
had low prevalence. Because PPV depends on the preva-
lence of the condition, it is not surprising that PPVs foridentifying these subgroups were low. A prior study has
reported claims data on diagnoses, procedures, and
healthcare utilization may not be good proxies for clin-
ical and laboratory values [10]. The current analysis
extends this prior finding and indicates claims data
have limited usefulness for identifying individuals with
a Framingham 10-year CHD risk score >20%.
Among participants at high risk for CHD events who
were using statins, algorithms identified those with LDL
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specified variables. As expected, the PPV for identifying
LDL cholesterol ≥70 mg/dL was higher (86%), due to higher
prevalence of the condition. However, true positives, false
positives, and false negatives differed on several characteris-
tics. The gain in PPV by using a claims-based algorithm to
identify individuals with LDL cholesterol ≥70 mg/dL may
not outweigh the potential loss in representativeness as
compared with all statin users at high risk for CHD events.
In comparison with using all available Medicare claims
prior to the REGARDS baseline study visit for each par-
ticipant, limiting Medicare claims to the one year period
prior to REGARDS baseline decreased the sensitivity for
identifying participants at high estimated risk for CHD
events. Evidently some Medicare beneficiaries with a his-
tory of cardiovascular conditions or risk factors do not
have sufficient evidence of those conditions or risk fac-
tors in recent diagnosis and procedure codes. Therefore,
studies in which participants’ Medicare history is limited
to a certain time period may tend toward underestimat-
ing the prevalence of high risk for CHD events.
To our knowledge, there are no prior reports of
claims-based algorithms for identifying high risk for
CHD events according to the ATP III definition. Pub-
lished claims-based definitions of several cardiovascular
conditions and procedures are available, and we incorpo-
rated these into our algorithms as pre-specified variables
[11-19]. In this study we attempted to go beyond specific
disease diagnoses to identify a more broadly-defined
group at high risk for CHD events according to ATP III
guidelines. As in the ATP III guidelines, the newly pub-
lished cholesterol treatment guidelines recommend that
treatment decisions be guided by risk for future events
as determined by medical history and estimated risk
based on measured risk factors [3]. Claims-based algo-
rithms to approximate clinical risk stratification may be
useful in future studies of outcomes of treatment with
novel LDL cholesterol lowering medications, in which
comparison groups would need to be identified.
Schneeweiss and colleagues found that the ability of
claims data to predict LDL cholesterol values was poor.
They concluded that in settings where LDL cholesterol
is a potential confounder, estimating missing LDL chol-
esterol values using claims may not substantially im-
prove confounding control [10]. Similarly, we found that
our algorithms did not identify representative groups of
statin users at high risk for CHD events who had uncon-
trolled LDL cholesterol. The new guidelines have less
focus on LDL treatment targets, but retain recommen-
dations to monitor LDL treatment response [3]. This
suggests that identifying comparison groups for pharma-
covigilance studies that are comparable in their LDL
cholesterol status and other characteristics may be diffi-
cult to accomplish using only claims data. It is alsoimportant in pharmacovigilance studies to identify com-
parison groups that would be similar in their risk for non-
CHD adverse events. Further work is required in this area.
This study has limitations. First, our classifications of
high risk groups were based partly on self-reported med-
ical history in REGARDS. Participants over-reporting or
under-reporting medical conditions may have resulted in
misclassification of true high risk status, diluting the
ability of algorithms to correctly identify target groups.
Second, we did not incorporate Medicare Part D phar-
macy claims into our algorithms. Part D was imple-
mented in 2006, with high penetration in the Medicare
population by 2007. However, most REGARDS in-home
visits occurred before 2007, and few REGARDS partic-
ipants had Part D coverage prior to their REGARDS
in-home visit. Including Part D pharmacy claims may
improve the ability to identify groups at high cardio-
vascular risk or with uncontrolled LDL cholesterol.
Third, the sample of REGARDS participants linked to
Medicare may not be representative of the overall
Medicare population enrolled in Parts A and B, where
we would hope to apply these algorithms. Also, Medi-
care Advantage plan enrollees were not included in
our study, so our algorithms may not be generalizable
to that subset of Medicare beneficiaries. Fourth, use
of claims data for identifying health-related variables
is limited by potential inaccuracies in the claims. For
example, administrative coding of diagnoses and pro-
cedures may be affected by reimbursement incentives,
random or systematic coding errors, or mismatches in
diagnostic resolution of available codes versus diag-
nostic resolution in clinical practice; these potential
biases may also fluctuate over time. This could be a
particular problem for documenting behavioral risk factors
like smoking. To maximize the accuracy of our algorithms
we used previously validated claims-based definitions of
diagnoses and procedures when such were available. Fifth,
we used an area-level income variable from Census data as
a pre-specified variable in our algorithms. Incorporating
individual-level income data for Medicare beneficiaries
could strengthen the algorithms.
Conclusions
In summary, we have demonstrated that claims-based
algorithms can be used to identify Medicare beneficiaries
at high risk for CHD events. Despite not having clinical or
laboratory data, Medicare claims have potential as a data
source for pharmacovigilance studies when groups at high
risk for CHD events need to be identified. Improving algo-
rithms for identifying subsets of high risk or groups with
uncontrolled LDL cholesterol will require further work.
Representativeness and generalizability will need to be
considered in interpreting the findings of future studies
conducted in cohorts identified by these algorithms.
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